# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
A First-In-Class, Broad-Spectrum Antiviral Agent Intending To Revolutionize Treatment of Viral Infections Including RSV, COVID,...
The Company has found that its lead nanoviricide broad-spectrum antiviral drug candidate NV-387, when given as a slow bolus i...